TROV Share Price

Open 0.72 Change Price %
High 0.73 1 Day -0.02 -2.74
Low 0.68 1 Week 0.00 0.00
Close 0.71 1 Month -0.13 -15.48
Volume 483607 1 Year -2.34 -76.72
52 Week High 3.50
52 Week Low 0.61
TROV Important Levels
Resistance 2 0.76
Resistance 1 0.74
Pivot 0.71
Support 1 0.68
Support 2 0.66
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

TrovaGene, Inc. (NASDAQ: TROV)

TROV Technical Analysis 4
As on 31st Oct 2017 TROV Share Price closed @ 0.71 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.29 & Sell for SHORT-TERM with Stoploss of 0.76 we also expect STOCK to react on Following IMPORTANT LEVELS.
TROV Target for November
1st Target up-side 0.93
2nd Target up-side 1.09
3rd Target up-side 1.25
1st Target down-side 0.49
2nd Target down-side 0.33
3rd Target down-side 0.17
TROV Other Details
Segment EQ
Market Capital 54819236.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.trovagene.com
TROV Address
TROV
11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States
Phone: 858-952-7570
TROV Latest News
Interactive Technical Analysis Chart TrovaGene, Inc. ( TROV NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TrovaGene, Inc.
TROV Business Profile
TrovaGene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�s urine-based test addresses market needs, such as women�s healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).